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Summary:
The use of peripheral blood stem cells (PBSC) in autolog-
In order to determine if peripheral blood stem cells ous transplantation (PBSCT) has demonstrated advantages (PBSC) collected after priming with G-CSF in AML in
over the use of marrow (ABMT) in several hematological first complete remission (CR) can be used for autologmalignancies and solid tumors. 1,2 In fact, a faster hematopoous transplantation and to evaluate the efficacy of early ietic reconstitution in PBSCT, resulting in lower infectious intensification therapy as in vivo purging, we studied 35 and haemorrhagic morbidity-mortality than in ABMT, has consecutive patients with AML in first CR. After stanbeen widely observed. 3, 4 These advantages are particularly dard induction and consolidation chemotherapy, 24 of evident in patients autografted for acute myelogenous leuthem were treated with one (10 patients) or two (14 kemia (AML), in whom engraftment is slower than in acute patients) cycles of high-dose cytarabine plus etoposide lymphocytic leukemia, and further delays occur as a conseprior to PBSC collection. G-CSF was used as the primquence of purging or heavy chemotherapy administered ing agent. Of the 35 patients scheduled for peripheral before marrow cell harvest. 5, 6 In addition, a lower freblood stem cell transplantation (PBSCT), three relapsed quency of neoplastic cells in peripheral blood has been before transplantation, and the 32 remaining underwent reported in this entity.
7,8

PBSCT. High-dose therapy consisted of either total
In recent years, different methods of mobilization to body irradiation plus cyclophosphamide or busulphan obtain peripheral blood progenitors have been developed. plus cyclophosphamide. The median number of CD34 + High-dose cyclophosphamide or polychemotherapy alone cells infused was 3.24 × 10 6 /kg (range 0. . The or associated with growth factors (mainly GM-CSF or Gmedian times to reach a PMN count of 0.5 × 10 9 /l and CSF) have generally yielded a good number of blood prea platelet count of 50 × 10 9 /l were 12 (8-28) and 30 (11-cursors, enough to assure an early engraftment. 9-12 How-345) days, respectively. There was no transplant-related ever, its use has been considerably reduced because of the mortality. Twelve patients relapsed between 2 and 21 dependence on 'timing' and the additional hematological months post-PBSCT. With a median follow-up of 28 and nonhematological toxicities. Lately, the capacity of a months, actuarial disease-free survival (DFS) is single growth factor to induce mobilization to peripheral 52.41 ؎ 9% in the intent-to-treat group and blood of hematopoietic precursors which are capable of 57.4 ؎ 9.8% in patients who underwent PBSCT. The restoring a complete and sustained hematopoiesis has freprobability of DFS is significantly higher for patients quently been reported. 13, 14 Nevertheless, the presence of who receive early intensification therapy prior to both GM or G-CSF receptors in leukemic blast cells, the PBSC collection and PBSCT as compared with patients reported capacity to stimulate their in vitro growth and the that do not: 68.8 ؎ 10.27% vs 35.5 ؎ 12.6%, P = 0.0418. description of disappointing clinical cases have limited their These results indicate the feasibility of PBSCT in AML employment as priming agents for PBSCT in AML. [15] [16] [17] using G-CSF-mobilized PBSC. The use of intensification The possibility of stimulating the growth of residual disease treatment as 'purging in vivo' prior both to collection and facilitating leukemic relapse has been presented as an of PBSC and PBSCT significantly reduces the risk of argument against the use of growth factor in this disease. consolidation treatment, without an available HLA-identical sibling, were offered autologous PBSCT using circulating peripheral blood progenitors (PBSC) collected only one course, which was administered as soon as CR employing G-CSF as the only priming agent. 23 Eligibility was reached, with the same drugs and dosages as used in for PBSCT required that the patient had an ECOG performinduction. ance status of 0 or 1 and adequate renal, hepatic and cardiac functions (creatinine clearance Ͼ70 ml/min, transaminases Post-induction/consolidation treatment Ͻ twice normal and bilirubin Ͻ34 mol/l and normal ejection fraction, respectively). Of the 41 patients who lacked Eleven out of the 35 patients scheduled for PBSCT a matched donor, six were assigned to chemotherapy underwent mobilization and PBSCT after consolidation (maintenance or intensive chemotherapy): three cases treatment and the remaining 24 patients received early because of transplantation refusal, one for psychological illintensification therapy following recovery from consoliness and two for poor performance status. The remaining dation treatment as part of a pilot study. Intensification 35 AML patients were assigned to PBSCT and entered in treatment consisted of one (10 cases) or two cycles (14 the study. Informed consent for PBSC collection and transcases) of high-dose cytarabine (1.5 g /m 2 twice daily during plantation was obtained from all patients. General characa 2-h i.v. infusion on days 1 to 3) and etoposide (100 mg/m 2 teristics of the patients are shown in Table 1 . once daily over 2 h i.v. infusion on days 1 to 3).
Induction and consolidation treatment Peripheral blood stem cell mobilization and collection
At least 1 month after the last intensification or consoliInduction therapy consisted of cytarabine (200 mg/m 2 /day by continuous i.v. infusion for 7 days) with either daunorudation course (if intensification was not administered), when patients were completely recovered, mobilization was bicin (45 mg/m 2 /day once daily i.v. for 3 days) (20 cases) or mitoxantrone (12 mg/m 2 /day once daily i.v. for 3 days) carried out (median 37 days, range 30-90). Human recombinant G-CSF (Amgen, Thousands Oaks, CA, USA) was (11 cases). Four patients with acute promyelocytic leukemia received ATRA at a dosage of 45 mg/m 2 /day p.o. until used as the priming agent at doses of 10 g/kg/day subcutaneously. The administration of G-CSF began 5 days before CR was achieved, followed by one (two patients) or two courses (two patients) of consolidation chemotherapy apheresis. On the 5th day, regardless of white blood cell count or any other hematological value, leukaphereses were (idarubicin + Ara-C). The patients who failed to achieve CR after one course of chemotherapy were given a second started and performed on consecutive days. G-CSF administration was continued daily until PBPC collection was course of induction chemotherapy identical to the first. The only patient who failed to achieve CR after two courses of completed, and did not have to be withdrawn from any patients because of adverse effects. Aphereses were perforAra-C + daunorubicin was treated with high-dose Ara-C (3 g/m 2 twice daily for 3 days) plus idarubicine and etoposide med using a continous flow blood cell separator COBE Spectra (COBE Laboratories, Lakewood, CO, USA) or CSand reached CR. Consolidation chemotherapy involved 3000 Plus (Fenwall, Round Lake, IL, USA). In all cases a bacterial treatment. Transfusions were given to maintain the hemoglobin above 8 g/dl and the platelet count above pre-apheresis hemoglobin level Ͼ100 g/l, a polymorphonuclear cell count Ͼ1.5 × 10 9 /l and a platelet count 20 × 10 9 /l. Single donor pheresed platelets were administered if a donor was available. All blood products were Ͼ100 × 10 9 /l were registered. Aphereses were performed until the total number of mononuclear cells (MNC) colirradiated with 20 Gy to avoid the risk of acute graft-versushost disease induction. lected reached 4 × 10 8 /kg body weight until January 1995, from which time the procedure was performed until an amount of 3 × 10 6 CD34 + cells/kg were collected. Statistical analysis A median of two aphereses per patient were performed. A total volume of between 7.8 to 16.8 l of blood was proClinical and laboratory data were recorded and analyzed by standard statistical methods using the SPSS software processed per apheresis at a blood flow rate of between 40-50 ml/min. The cell suspension collected was immediately gram. Events up to 30 April 1997 were included in the analysis. The Wilcoxon rank-sum test was used to compare frozen in a controlled rate freezer after each apheresis using DMSO 10% v/v as cryoprotectant and stored in liquid nitromeans for continuous data. The 2 test was applied for comparison of categorical variables among subgroups. Diseasegen at Ϫ196°C until use.
free survival (DFS) was defined as the time from CR to relapse or death and survival as the time from diagnosis to Quantification of CD34 + cells death due to any cause. The Kaplan-Meier product-limit estimates were used to evaluate actuarial DFS, actuarial Samples of aphereses were freshly analyzed; 0.5-1 × 10 6 cells/ml were stained with fluorescein isothiocyanate or relapse and survival and for obtaining curves of granulocyte and platelet recovery and transfusion independence. phycoerythrin-conjugated CD34 antibody (HPCA2; Becton Dickinson, San José, CA, USA) and incubated for 20 min
Comparison between actuarial curves were made using the log-rank test. Factors likely to be associated with relapse in the dark. After two washes with PBS containing 0.5% BSA and 0.2% sodium azide (w/v), red cells were lysed and survival were studied by multivariate Cox regression analysis. using ammonium chloride. FITC or PE isotypic antibodies were used as controls. Analyses were carried out on a EPICs-Profile or EPICs-Elite cytometer (Coulter, Hialeah, FL, USA) equipped with an argon laser tuned to 488 nm.
Results
CD34
+ cells were defined by side-scattered and fluorescence characteristics.
Among the 35 intent-to-treat patients, nine (27%) required two cycles of remission induction chemotherapy. None of the patients scheduled for PBSCT who received intensifiPretransplant regimens cation treatment died during intensification nor were removed from the study because of toxicity. Only two Thirty-two patients received the pretransplant conditioning regimen. Eighteen patients received fractionated total body patients suffered mild cerebellar toxicity due to high-dose cytarabine but this was reversible and did not influence the irradiation (FTBI) delivered in eight fractions of 165 cGy from day Ϫ7 to Ϫ4 (total dose 13.2 Gy, lung dose limited timing of PBSCT. One patient developed systemic candidiasis during the first intensification course which resolved to 9 Gy) and cyclophosphamide (CY) (60 mg/kg once daily on days Ϫ3 and Ϫ2). Fourteen patients were given busulwith Amphotericin B, and she was able to undergo PBSCT. phan (4 mg/kg p.o. in divided doses daily from day Ϫ8 to Ϫ5, total dose 16 mg/kg) followed by CY (60 mg/kg once Peripheral blood stem cell collection daily i.v. on days Ϫ4 and Ϫ3). Phenytoin was begun 2 days before high-dose treatment as prophylaxis against busThirty-five patients underwent PBSC collections following mobilization with G-CSF alone 1.5 to 8.5 months (median ulphan-induced seizures. At the time of PBSCT (day 0), each bag was rapidly thawed in a 38°C water bath and 3 months) after CR. A median of 3.24 × 10 6 /kg CD34 + cells (range 0.15-14) and 4.8 × 10 6 /kg MNC (range 3.38-7.5) infused through a central venous catheter over 10 to 15 min. Regimen-related toxicity was assessed using WHO criteria.
were collected in a median of two aphereses (range 1-4). There was no difference in the number of aphereses performed on the cohort of patients who received intensification Supportive therapy treatment and those that did not. Results of mobilization are shown in Table 2 . A higher number of CD34 + cells Patients were maintained in a laminar air flow or positive pressure room from the first day of hospitalization until was collected in the group of patients that did not receive intensification treatment (3.92 × 10 6 /kg vs 2.92 × 10 6 /kg), discharge. They received oral ciprofloxacin and antifungal prophylaxis in the form of oral fluconazol, nystatin but the difference did not reach statistical significance (P = 0.1726). mouthwash or both. Anti-CMV hyperimmune immunoglobulin (Globuman; Institut Sérotherápique et Vaccinal Suisse Berne, Berne, Switzerland) was administered to 14 Peripheral blood stem cell transplantation of the patients at a dose of 150 mg/kg from day +1 until day +86. When fever exceeded 38°C, broad spectrum antiAmong 35 patients scheduled for PBSCT, three (8.6%) were unable to proceed to PBSCT. Two patients, affected biotics were administered. Amphotericin B was given when fever persisted for more than 5 days despite appropiate antiby M4 subtype, relapsed after collection of PBSC just + cells, numtreatment. Another patient (M3 subtype) was unable to undergo PBSCT due to hepatopathy of unknown origin. In ber of MNC and number of CFU-GM infused were analyzed for their role in engraftment. In the multivariate Cox this case, PBSC were collected after one consolidation course and he relapsed 3 months later. A second CR was regression analysis, only the number of prior chemotherapy regimens and the number of CFU-GM infused were sigachieved and an allogeneic BMT from a unrelated donor was performed, and he is alive and disease-free 37 months nificant for granulocyte engraftment, whereas the number of CD34 + cells infused Ͼ2.5 × 10 6 /kg and age at PBSCT after. Therefore, PBSCT was performed in 32 (91.4%) of the patients scheduled for PBSCT. The median interval were significant for platelet engraftment (Table 3) . As is shown in Table 2 , there were no differences time between CR documentation and PBSCT was 5 months (range 2-9 months).
between patients who received intensification and those that did not in the number of febrile days, days of antibiotic treatment or days of hospitalization.
Hematopoietic reconstitution
The requirements for packed red blood cell and platelet transfusion are shown in Table 2 . No significant difference All patients reached a complete granulocyte recovery. The median number of days needed to reach a PMN count was found in the number of red blood cells or platelet units transfused between the group that received intensification greater than 0.5 × 10 9 /l and greater than 1 × 10 9 /l in patients in whom intensification chemotherapy had not been admintreatment and the group that did not. istered was 13 days (range 10-24) and 16 days (range 10-41) respectively, vs 12 days (8-28) and 13.5 days (range 9-100) in patients in whom it had (P = 0.20, P = 0.58).
PBSCT-related complications and mortality Only one patient had to receive a prolonged course of G-CSF after PBSCT (35 days) until he reached a stable There were no procedure-related deaths. There was one case of busulphan-associated seizures and two cases of 0.5 × 10 9 PMN/l count. The median number of days needed to reach a platelet count without platelet transfusion greater hemorrhagic cystitis, which were resolved at 10 and 7 days from the onset. Mucositis was the conditioning-related toxthan 50 × 10 9 /l was 23 days (range 15-300) in the former group and 33 days (11-345) in patients in whom intensifiicity most frequently seen (83% of patients, grade уII: 40%). 80% of patients developed fever and required antication was administered (P = 0.91 /l, developed pancytopenia from day +400 post-PBSCT and she remains platelet and red cell blood transliposomal amphotericin B for prophylaxis against reactivation of hepatosplenic candidiasis. None of the patients fusions dependent +22 months after PBSCT without evidence of recurrent leukemia on repeated bone marrow had pneumonitis or VOD. Patient UPN 97 suffered subarachnoid hemorrhage on day +120 due to thrombocytopenia, examinations. Another three patients did not reach platelets у50 × 10 9 /l (UPN 97, 90, 101) although doses of CD34 + she recovered and relapsed later. There has been no longterm morbidity from the procedure and all survivors, except cells infused were 3, 4 and 3.93 × 10 6 /kg respectively, and they relapsed early after PBSCT (days +60, +180, +120 patient UPN 112, aged 63 years (the oldest of our series) 379  Table 3 Multivariate analysis of variables affecting engraftment who is dependent on red blood cells and platelets transand DFS (Ϯ s.e.) at 4 years are 46.6 Ϯ 9.4% and 52.4 Ϯ 9.4% for the 35 patients with intent-to-undergo fusions, have an ECOG performance status of 0.
PBSCT and 42.6 Ϯ 9.8% and 57.4 Ϯ 9.8% for the 32 patients who underwent PBSCT, respectively. Twelve complete remission. If we consider patients who underwent a rapid, complete and stable hematopoietic recovery in patients with AML in first CR undergoing PBSCT. Like PBSCT, DFS was significantly better for patients who received intensification treatment compared with patients other authors who have described their results in PBSCT using different methods of mobilization of progenitors such that underwent PBSCT after consolidation treatment (Figure 1 ): 68.82 Ϯ 10.27% vs 35.50 Ϯ 12.6% (P = as polychemotherapy or cyclophosphamide either alone or associated with growth factors, we report a shortening of 0.0418). Futhermore, these figures improve in those patients who received two intensification courses (13 the pancytopenic period and therefore, a reduction of the resulting complications and mortality due to neutropenia cases): 81.62 Ϯ 10.01%, with only two relapses. However, in the intent-to-treat group, the difference in DFS between and thrombocytopenia.
2-4,9,10, 14, 21 There is little experience of G-CSF-mobilized PBSC in patients who received intensification therapy and those that did not did not reach statistical signification patients with AML due to previously reported findings about the existence of G-CSF receptors in myeloblasts, 15 (62.22 Ϯ 10.09% vs 34.09 Ϯ 12.3%, P = 0.13). Factors likely to be associated with DFS and the probincreased capacity to stimulate the in vitro growth 16, 17 and isolated unfortunate clinical cases. In the same way, some ability of survival were studied by the stepwise Cox regression model. The factors examined are shown in Table  authors have reported a trend towards a higher relapse rate in patients with AML receiving PBSC compared with 4. The analysis did not show any relationship between DFS or the probability of relapse and age, sex, FAB subtypes patients receiving purged marrow. Mehta et al 18 reported four patients in whom they used cytokine-mobilized (M3 vs others, Mo-M3 vs M4-M5), number of induction courses (1/2), time from CR to PBSC collection, time from PBSCT and all four patients relapsed rapidly. This author and Laporte et al 24 also speculated that PBSCT for acute CR to PBSCT, type of conditioning regimen. The only factors that influence DFS were: positively, the application of leukemia may result in higher relapse rates than autologous BMT due to the reinfusion of a higher number of malignant intensification treatment (P = 0.01; relative risk (RR): 1.9) and negatively, an elevated initial WBC count (P = 0.0115; cells. Demirer et al 25 reported a series of 33 AML patients that underwent autologous transplant of PBSC collected RR = 1).
after rhG-CSF with or without chemotherapy, with a probability of relapse of 65% at 2 years, but the procedure was Survival performed on patients in untreated relapse or second CR.
However, in the current study using G-CSF-mobilized The 4-year actuarial survival is 52.02 Ϯ 10.47% for the intent to treat group and 52.34 Ϯ 10.67% for patients who PBSC, we report a DFS of 52.4% for the intent-to-treat group and 57.4% for patients who underwent PBSCT, underwent PBSCT. Using the Cox model none of the factors examined earlier were found to be statistically signifiresults that are comparable to studies that used purged marrow 26-28 (DFS of 54 to 63%) and somewhat better than cant for the probability of survival except an elevated initial WBC count (P = 0.011; RR = 1). A trend of a better probother studies using unpurged marrow 26,29,30 (range 34-56.5%) or using PBSC collected during the recovery phase ability of survival is observed for patients who received intensification treatment, (57.42 Ϯ 13.7% vs 36 Ϯ 16%) but of induction or consolidation chemotherapy 9,10,21,31 (range 35-39%). the difference does not reach statistical significance (P = 0.1105).
An important finding emerges from our results: the positive role of early intensification therapy prior to the harvest of progenitor cells in the prevention of relapse after PBSCT: the estimated probability of relapse is significantly Discussion lower (31.18 Ϯ 10.2% in patients who underwent intensification treatment as compared with 64.5 Ϯ 12% in patients Our study demonstrates that mobilization with G-CSF alone provides enough hematopoietic progenitors to assure who received PBSCT after consolidation treatment, P = 32 showed that risk of relapse and notably increases the probability of disease-free survival in this group of patients. the number of courses of post-remission chemotherapy before the harvest and ABMT was the most significant factor associated with decreased relapse. The early intensification treatment was intended to reduce the tumor burden References in both the patient and in the PBSC collected and used as inoculum ('in vivo purging'). Our results support this 
